Antithrombotic Drugs Market

Global Antithrombotic Drugs Market By Route of Administration (Oral and Parenteral), By Application (Deep Vein Thrombosis, Atrial Fibrillation, Pulmonary Embolism, and Others) - Global Industry Share, Growth, Competitive Analysis And Forecast Period 2020-2027

Published: May 2020 | Report Code: OMR2023828 | Category : Pharmaceuticals | Delivery Format: /

The global antithrombotic drugs market is projected to grow at a CAGR of around 7.5% during the forecast period. The market growth is attributed to various factors such as the growing incidence and prevalence of blood-related diseases such as deep vein thrombosis, pulmonary embolism, strokes, and heart attack. Increasing geriatric population and obesity is the main cause of clotting which lead to the growth of the market. 

However, some factors are expected to restrain the market growth that includes lack of health infrastructure in low economic countries, high cost of medicines, and side effects of the treatment. However, promotional initiatives and campaigns to raise awareness about the problems caused by a blood clot and their treatments, increasing healthcare spending, and extensive collaborations between market players are the factors that are creating growth opportunities for the antithrombotic drugs market across the globe.

Segmental Outlook 

The global antithrombotic drugs market is segmented on the basis of route of administration and application. Based on the route of administration, the market is bifurcated into the oral route of administration and parenteral route of administration. On the basis of application, the market is segmented into deep vein thrombosis, atrial fibrillation, pulmonary embolism, and others. 

Global Antithrombotic Drugs Market by Route of Administration, 2020 (%)

 Global Antithrombotic Drugs Market by Route of Administration

Among the route of administration, the parenteral route is estimated to hold a prominent share owing to its onset of action and the presence of a notable number of products in the market. Further, on the basis of application, deep vein thrombosis is projected to exhibit considerable growth during the forecast period. The growth is attributed to the prevalence and sedentary lifestyle among the population that is leading to cardiovascular diseases.

Regional Outlooks

Geographically, the study of the global antithrombotic drugs market covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), and the Rest of the World. North America rules the market with the highest incidence of deep vein thrombosis. In addition, there are advanced technologies and developed healthcare infrastructure in the region that propels the growth in North America. Europe stands second in the race due to the high rate of diagnosis and treatment, the ability to introduce innovations by investing in research and development, and the presence of good healthcare facilities. 

Asia-Pacific is anticipated to exhibit significant growth during the forecast period due to the rising consciousness among people, developing technology and healthcare amenities, and the presence of a large number of the patient pool. Increasing healthcare spending of people and campaigns to raise awareness about the disease and the treatment will drive the market growth in the region.

Market Players Outlook

Some of the key players of the antithrombotic drugs market include Bayer AG, Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Co., Boehringer Ingelheim GmbH, and others. In order to survive in the market, these players adopt different marketing strategies such as a merger, acquisitions, product launch, and geographical expansion. 

The Report Covers

  • Market value data analysis of 2020 and forecast to 2027.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global antithrombotic drugs market. Based on the availability of data, information related to new Drug type launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market.

1. Report Summary

Current Industry Analysis and Growth Potential Outlook

Impact of COVID-19 on the Global Antithrombotic Drugs Market

Recovery Scenario of Global Antithrombotic Drugs Market

1.1. Research Methods and Tools

1.2. Market Breakdown

1.2.1. By Segments

1.2.2. By Geography

2. Market Overview and Insights

2.1. Scope of the Report

2.2. Analyst Insight & Current Market Trends

2.2.1. Key Findings

2.2.2. Recommendations

2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis

3.1.1. Overview

3.1.2. Financial Analysis 

3.1.3. SWOT Analysis

3.1.4. Recent Developments

3.2. Key Strategy Analysis

4. Market Determinants

4.1. Motivators

4.2. Restraints

4.3. Opportunities

5. Market Segmentation

5.1. Antithrombotic Drugs Market By Route Of Administration

5.1.1. Oral 

5.1.2. Parenteral

5.2. Antithrombotic Drugs Market By Application

5.2.1. Deep Vein Thrombosis

5.2.2. Atrial Fibrillation

5.2.3. Pulmonary Embolism

5.2.4. Others

6. Regional Analysis

6.1. North America

6.1.1. United States

6.1.2. Canada

6.2. Europe

6.2.1. UK

6.2.2. Germany

6.2.3. Italy

6.2.4. Spain

6.2.5. France

6.2.6. Rest of Europe 

6.3. Asia-Pacific

6.3.1. China

6.3.2. India

6.3.3. Japan

6.3.4. Rest of Asia-Pacific 

6.4. Rest of the World

7. Company Profiles 

7.1. Aspen Holdings

7.2. Athersys, Inc.

7.3. Bayer AG

7.4. Boehringer Ingelheim GmbH

7.5. Bristol-Myers Squibb Co.

7.6. Daiichi Sankyo Co.

7.7. Eli Lilly and Company

7.8. GlaxoSmithKline Plc

7.9. Inari Medical, Inc.

7.10. Microbix Biosystems Inc.

7.11. Pfizer Inc.

7.12. Portola Pharmaceuticals, Inc.

7.13. Sanofi S.A.

7.14. Teva Pharmaceutical Industries Ltd.

1. GLOBAL ANTITHROMBOTIC DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2020-2027 ($ MILLION) 

2. GLOBAL ORAL ANTITHROMBOTIC DRUGS MARKET  RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

3. GLOBAL PAREMTERAL ANTITHROMBOTIC DRUGS MARKET  RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

4. GLOBAL ANTITHROMBOTIC DRUGS MARKET RESEARCH AND ANALYSIS, BY APPLICATION, 2020-2027 ($ MILLION)

5. GLOBAL DEEP VEIN THROMBOSIS DRUGS MARKET  RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

6. GLOBAL ATRIAL FIBRILLATION DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

7. GLOBAL PULMONARY EMBOLISM DRUGS MARKET  RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

8. GLOBAL OTHER DRUGS MARKET  RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

9. NORTH AMERICAN ANTITHROMBOTIC DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2020-2027 ($ MILLION)

10. NORTH AMERICAN ANTITHROMBOTIC DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)

11. NORTH AMERICAN ANTITHROMBOTIC DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)

12. EUROPEAN ANTITHROMBOTIC DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2020-2027 ($ MILLION)

13. EUROPEAN ANTITHROMBOTIC DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)

14. EUROPEAN ANTITHROMBOTIC DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)

15. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2020-2027 ($ MILLION)

16. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)

17. ASIA PACIFIC ANTITHROMBOTIC DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)

18. REST OF THE WORLD ANTITHROMBOTIC DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2020-2027 ($ MILLION)

19. REST OF THE WORLD ANTITHROMBOTIC DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)

1. GLOBAL ANTITHROMBOTIC DRUGS MARKET SHARE BY ROUTE OF ADMINISTRATION, 2020 VS 2027 (%)

2. GLOBAL ANTITHROMBOTIC DRUGS MARKET SHARE BY APPLICATION, 2020 VS 2027 (%)

3. GLOBAL ANTITHROMBOTIC DRUGS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)

4. GLOBAL ORAL ANTITHROMBOTIC DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)

5. GLOBAL PARENTERAL ANTITHROMBOTIC DRUGS MARKET SHARE BY REGION, 2020 VS 2027 (%)

6. GLOBAL DEEP VEIN THROMBOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)

7. GLOBAL ATRIAL FIBRILLATION MARKET SHARE BY REGION, 2020 VS 2027 (%)

8. GLOBAL PULMONARY EMBOLISM MARKET SHARE BY REGION, 2020 VS 2027 (%)

9. GLOBAL OTHER APPLICATION MARKET SHARE BY REGION, 2020 VS 2027 (%)

10. US ANTITHROMBOTIC DRUGS MARKET SIZE, 2020-2027 ($ MILLION)

11. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, 2020-2027 ($ MILLION)

12. UK ANTITHROMBOTIC DRUGS MARKET SIZE, 2020-2027 ($ MILLION)

13. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, 2020-2027 ($ MILLION)

14. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, 2020-2027 ($ MILLION)

15. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, 2020-2027 ($ MILLION)

16. SPAIN ANTITHROMBOTIC DRUGS MARKET SIZE, 2020-2027 ($ MILLION)

17. REST OF EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, 2020-2027 ($ MILLION)

18. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, 2020-2027 ($ MILLION)

19. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, 2020-2027 ($ MILLION)

20. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, 2020-2027 ($ MILLION)

21. REST OF ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, 2020-2027 ($ MILLION)

22. REST OF THE WORLD ANTITHROMBOTIC DRUGS MARKET SIZE, 2020-2027 ($ MILLION)